Literature DB >> 23726913

Sialic acid-dependent attachment of mucins from three mouse strains to Entamoeba histolytica.

Kentaro Kato1, Yasuhiro Takegawa, Katherine S Ralston, Carol A Gilchrist, Shinjiro Hamano, William A Petri, Yasuro Shinohara.   

Abstract

Mouse strain-specific differences in the carbohydrate composition of intestinal mucins were hypothesized to account for strain-dependent susceptibility to Entamoeba histolytica. To test this hypothesis, intestinal mucins from susceptible and resistant inbred strains of mice were analyzed for their O-glycan content and for their ability to inhibit amoebic adherence to (GalNAc)12-27-HSA neo-glycoproteins. The results showed that the colorectal mucin O-glycan of susceptible CBA mice was lower in sialic acid content than that of resistant C57BL/6 and BALB/c mice. Mucins from CBA mice were more potent inhibitors of E. histolytica adherence to neo-glycoproteins than were mucins from C57BL/6 or BALB/c mice. Consistent with the role of terminal Gal/GalNAc as a receptor for amoebic adherence, sialidase treatment of C57BL/6 and BALB/c colorectal mucins increased their ability to inhibit E. histolytica adherence to the neo-glycoproteins. These results provide evidence of mouse strain-specific differences in the sialic acids content of mucin O-glycans. These dissimilarities likely contribute to the differential susceptibility of the three mouse strains to E. histolytica infection.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23726913      PMCID: PMC3734206          DOI: 10.1016/j.bbrc.2013.05.085

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

Review 1.  From mucins to mucus: toward a more coherent understanding of this essential barrier.

Authors:  David J Thornton; John K Sheehan
Journal:  Proc Am Thorac Soc       Date:  2004

Review 2.  Characterization of mouse sialyltransferase genes: their evolution and diversity.

Authors:  Shou Takashima
Journal:  Biosci Biotechnol Biochem       Date:  2008-05-07       Impact factor: 2.043

3.  Functional heterogeneity of colonic adenocarcinoma mucins for inhibition of Entamoeba histolytica adherence to target cells.

Authors:  M U Göttke; K Keller; A Belley; R M Garcia; M A Hollingsworth; D R Mack; K Chadee
Journal:  J Eukaryot Microbiol       Date:  1998 Mar-Apr       Impact factor: 3.346

4.  Resistance to intestinal Entamoeba histolytica infection is conferred by innate immunity and Gr-1+ cells.

Authors:  Amon Asgharpour; Carol Gilchrist; Duza Baba; Shinjiro Hamano; Eric Houpt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

Review 5.  Epithelial mucin genes.

Authors:  S J Gendler; A P Spicer
Journal:  Annu Rev Physiol       Date:  1995       Impact factor: 19.318

Review 6.  Infection, inflammation and host carbohydrates: a Glyco-Evasion Hypothesis.

Authors:  Lori Sc Kreisman; Brian A Cobb
Journal:  Glycobiology       Date:  2012-04-05       Impact factor: 4.313

Review 7.  The bittersweet interface of parasite and host: lectin-carbohydrate interactions during human invasion by the parasite Entamoeba histolytica.

Authors:  William A Petri; Rashidul Haque; Barbara J Mann
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

8.  High affinity binding of the Entamoeba histolytica lectin to polyvalent N-acetylgalactosaminides.

Authors:  P Adler; S J Wood; Y C Lee; R T Lee; W A Petri; R L Schnaar
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

9.  Isolation of the galactose-binding lectin that mediates the in vitro adherence of Entamoeba histolytica.

Authors:  W A Petri; R D Smith; P H Schlesinger; C F Murphy; J I Ravdin
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

10.  Expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase isoforms in murine tissues determined by real-time PCR: a new view of a large family.

Authors:  William W Young; Dana R Holcomb; Kelly G Ten Hagen; Lawrence A Tabak
Journal:  Glycobiology       Date:  2003-03-19       Impact factor: 4.313

View more
  5 in total

1.  Influenza A virus alters pneumococcal nasal colonization and middle ear infection independently of phase variation.

Authors:  John T Wren; Lance K Blevins; Bing Pang; Lauren B King; Antonia C Perez; Kyle A Murrah; Jennifer L Reimche; Martha A Alexander-Miller; W Edward Swords
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

2.  Pneumococcal Neuraminidase A (NanA) Promotes Biofilm Formation and Synergizes with Influenza A Virus in Nasal Colonization and Middle Ear Infection.

Authors:  John T Wren; Lance K Blevins; Bing Pang; Ankita Basu Roy; Melissa B Oliver; Jennifer L Reimche; Jessie E Wozniak; Martha A Alexander-Miller; W Edward Swords
Journal:  Infect Immun       Date:  2017-03-23       Impact factor: 3.441

Review 3.  Entamoeba histolytica: adhesins and lectins in the trophozoite surface.

Authors:  Magdalena Aguirre García; Laila Gutiérrez-Kobeh; Rosario López Vancell
Journal:  Molecules       Date:  2015-02-09       Impact factor: 4.411

4.  Escherichia coli mediated resistance of Entamoeba histolytica to oxidative stress is triggered by oxaloacetate.

Authors:  Yana Shaulov; Chikako Shimokawa; Meirav Trebicz-Geffen; Shruti Nagaraja; Karen Methling; Michael Lalk; Lea Weiss-Cerem; Ayelet T Lamm; Hajime Hisaeda; Serge Ankri
Journal:  PLoS Pathog       Date:  2018-10-11       Impact factor: 6.823

5.  Assessing the function of pneumococcal neuraminidases NanA, NanB and NanC in in vitro and in vivo lung infection models using monoclonal antibodies.

Authors:  Philipp Janesch; Harald Rouha; Adriana Badarau; Lukas Stulik; Irina Mirkina; Marisa Caccamo; Katharina Havlicek; Barbara Maierhofer; Susanne Weber; Karin Groß; Jacqueline Steinhäuser; Manuel Zerbs; Cecilia Varga; Ivana Dolezilkova; Sabine Maier; Gerhild Zauner; Nels Nielson; Christine A Power; Eszter Nagy
Journal:  Virulence       Date:  2018       Impact factor: 5.882

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.